Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1267434 | 0.96 | KCNH2 (0.52) | KCNH2SLC2A1 | |
| SCHEMBL1267766 | 0.96 | KCNH2 (0.52) | KCNH2SLC2A1 | |
| SCHEMBL1266600 | 0.92 | SLC2A1 (0.44) | KCNH2SLC2A1 | |
| SCHEMBL1266845 | 0.92 | SLC2A1 (0.44) | KCNH2SLC2A1 | |
| SCHEMBL1267838 | 0.88 | KCNH2 (0.48) | KCNH2 | |
| SCHEMBL1267836 | 0.88 | KCNH2 (0.48) | KCNH2 | |
| SCHEMBL1266354 | 0.84 | KCNH2 (0.49) | KCNH2SLC2A1 | |
| SCHEMBL1266355 | 0.84 | KCNH2 (0.49) | KCNH2SLC2A1 | |
| SCHEMBL1267161 | 0.83 | KCNH2 (0.59) | KCNH2 | |
| SCHEMBL1266713 | 0.83 | KCNH2 (0.59) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039836-A1 | TRICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-17 | — | — | US | claimed |
| US-8012961-B2 | Tricyclic antibiotics | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-09-06 | — | — | US | disclosed |
| US-20110039836-A1 | TRICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039836-A1 | TRICYCLIC ANTIBIOTICS | OPRM1, UBE2D3, METTL3 | KCNH2 924/4885SLC2A1 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.